Zebrafish screens for new colitis treatments - a bottom-up approach.
Many factors interact in the development and progression of inflammatory bowel disease. This complexity demands a combination of methods to disentangle the pathology of this disease. As reported by Oehlers et al. in this issue, the zebrafish drug screen is one simple approach that could enable the elucidation of the pathways involved in IBD and ultimately the discovery of new therapeutics.
The Bateson Centre and Department of Infection, Immunity and Cardiovascular Disease, the University of Sheffield, Sheffield, UK.
Jou A
JA
Lee
The Bateson Centre and Department of Infection, Immunity and Cardiovascular Disease, the University of Sheffield, Sheffield, UK.
Stephen A
SA
Renshaw
D000818:Animals; D030801:Animals, Genetically Modified; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D003093:Colitis, Ulcerative / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D003424:Crohn Disease / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D016264:Dextran Sulfate; D004195:Disease Models, Animal; D064806:Dysbiosis / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D057166:High-Throughput Screening Assays; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology*; D007422:Intestines / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D014302:Trinitrobenzenesulfonic Acid; D015027:Zebrafish
D000893:Anti-Inflammatory Agents; D007155:Immunologic Factors; D014302:Trinitrobenzenesulfonic Acid; D016264:Dextran Sulfate